Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.
IPO Year: 2021
Exchange: NASDAQ
Website: designtx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/7/2024 | $6.00 → $12.00 | Neutral → Overweight | Piper Sandler |
| 11/14/2023 | $42.00 → $6.00 | Overweight → Neutral | Piper Sandler |
| 8/15/2023 | $19.00 → $6.00 | Outperform → Neutral | Wedbush |
| 8/15/2023 | $23.00 → $7.00 | Outperform → Sector Perform | RBC Capital Mkts |
| 8/15/2023 | $6.00 | Outperform → Market Perform | SVB Securities |
| 5/4/2023 | $6.00 | Sell → Neutral | Goldman |
| 6/10/2022 | $21.00 | Outperform | Wedbush |
| 5/2/2022 | $30.00 | Outperform | RBC Capital Mkts |
| 1/19/2022 | $10.00 | Sell | Goldman Sachs |
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
10-Q - Design Therapeutics, Inc. (0001807120) (Filer)
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
10-Q - Design Therapeutics, Inc. (0001807120) (Filer)
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
10-Q - Design Therapeutics, Inc. (0001807120) (Filer)
8-K - Design Therapeutics, Inc. (0001807120) (Filer)
ARS - Design Therapeutics, Inc. (0001807120) (Filer)
DEFA14A - Design Therapeutics, Inc. (0001807120) (Filer)
DEF 14A - Design Therapeutics, Inc. (0001807120) (Filer)
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi
DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical
DT-216 was Generally Well-Tolerated and Resulted in a More than Doubling of Frataxin mRNA in Patients with Friedreich Ataxia Second GeneTACTM Development Candidate, DT-168, Selected for the Treatment of Fuchs Endothelial Corneal Dystrophy Administered as an Eye Drop; IND Expected in 2023 Advancing Myotonic Dystrophy Type-1 GeneTACTM Lead Molecules; IND Expected in 2024 Conference Call to be Held Today at 4:30pm ET CARLSBAD, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported progress across its portfolio of novel GeneTAC™ small molecules.
Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e
CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company's first clinical trial planned to begin in the first half of 2022. "I am thrilled to welcome Jae to Design, particularly as we prepare to embark on the important transition to a clinical stage company and initiation of our Phase 1 clinical trial in patients with Friedreich ataxia," said João Siffert, M.D., president and chief execut
Preclinical Data Support Initiation of Clinical Development of Lead GeneTAC Program for Friedreich Ataxia in the First Half of 2022 Leadership Team Strengthened with Appointment of Elizabeth Gordon, Ph.D., as Senior Vice President of Regulatory Affairs CARLSBAD, Calif., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported recent progress with its portfolio of novel small molecule gene targeted chimeras (GeneTACsTM), as well as business highlights and second quarter 2021 financial results. "So far in 2021, we've made substantial progress as a company, highlighted by the
Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously
Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously
Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously
RBC Capital Mkts downgraded Design Therapeutics from Outperform to Sector Perform and set a new price target of $7.00 from $23.00 previously
SVB Securities downgraded Design Therapeutics from Outperform to Market Perform and set a new price target of $6.00
Goldman upgraded Design Therapeutics from Sell to Neutral and set a new price target of $6.00
Wedbush initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $21.00
RBC Capital Mkts initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $30.00
Goldman Sachs initiated coverage of Design Therapeutics with a rating of Sell and set a new price target of $10.00
SVB Leerink initiated coverage of Design Therapeutics with a rating of Outperform and set a new price target of $36.00
CARLSBAD, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in the following upcoming investor conferences: 2024 Jefferies London Healthcare ConferencePresentation: Tuesday, November 19, 2024, at 10:00 a.m. GMTLocation: London, UK Piper Sandler 36th Annual Healthcare ConferenceFireside Chat: Tuesday, December 3, 2024, at 11:30 a.m. ETLocation: New York, NY Live webcasts of the presentations will be available here and in the investors section of the company's website at www.designtx.com. The webcasts will
Fuchs Endothelial Corneal Dystrophy (FECD) Phase 1 Trial Initiated with Data Expected in the First Half of 2025 Friedreich Ataxia (FA) Program on Track to Initiate Phase 1 Single Ascending Dose, Healthy Volunteer Study in the First Half of 2025 Active Research Pipeline Advancing with Programs in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Well-Capitalized with Cash and Securities of $254.1 Million to Fund Operations Through Up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic dise
CARLSBAD, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 Cantor Global Healthcare Conference on Thursday, September 19, 2024, at 12:45 p.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a biotechnology company developing a new class of therapies based on its p
Friedreich Ataxia (FA) and Fuchs Endothelial Corneal Dystrophy (FECD) Programs on Track and Advancing Toward Clinical Trials Active Research Pipeline with Programs Progressing in Myotonic Dystrophy Type-1 (DM1) and Huntington's Disease (HD) Cash and Securities of $261.0 Million Supports Operations Through Potentially Four Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced its second quarter 2024 financial results and reviewed upcoming program milestones for its portfolio of GeneTAC™ candidates. "In the s
Advancing DT-216P2, New Drug Product for Friedreich Ataxia (FA), Toward Clinical Trials Starting Phase 1 Development for Fuchs Endothelial Corneal Dystrophy (FECD) in 2024; Observational Study Currently Enrolling Patients Progressing GeneTACTM Pipeline Programs in Huntington's Disease (HD) and Myotonic Dystrophy Type-1 (DM1) to Development Candidates Cash and Securities of $270.7 Million Support Multi-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-of-Concept CARLSBAD, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today an
CARLSBAD, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2024 RBC Capital Markets Healthcare Conference on Wednesday, May 15, 2024, at 11:30 a.m. ET in New York. A live webcast of the fireside chat will be available here and in the investors section of the company's website at www.designtx.com. The webcast will be archived for 30 days following the presentation. About Design TherapeuticsDesign Therapeutics is a biotechnology company developing a new class of therapies based on its platform of
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra
CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi
Seasoned Biotech Executive Pratik Shah Appointed as Chief Executive Officer to Lead Company Turnaround Current Cash and Securities of ~$290M Support Extended Five-Year Operating Runway Through 2028 Revised Corporate Strategy with Realignment Towards Long-Term Growth to be Presented in Early 2024; Additional Details to Follow CARLSBAD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today reported third quarter 2023 financial results. A strategic realignment was initiated to prioritize long-term growth, focus capital resources on program spend and implement cost sav
Initial Data from Phase 1 Multiple-Ascending Dose Trial of DT-216 for Friedreich Ataxia Showed Significant Increase in FXN mRNA Levels in Skeletal Muscle Company Expects to Resume a Multiple Dose Phase 1 Clinical Study with DT-216 with an Improved Formulation in the Second Half of 2024 and Report Data in the First Half of 2025 IND Submission for FECD GeneTAC™ Program On-track for the Second Half of 2023 $303.1 Million in Cash and Securities Expected to Support Operating Runway through 2026 CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, t
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
4 - Design Therapeutics, Inc. (0001807120) (Issuer)
3 - Design Therapeutics, Inc. (0001807120) (Issuer)
SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G - Design Therapeutics, Inc. (0001807120) (Subject)
SC 13G - Design Therapeutics, Inc. (0001807120) (Subject)
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.20) per share which beat the analyst consensus estimate of $(0.29) by 31.03 percent. This is a 42.86 percent increase over losses of $(0.35) per share from the same period last year.
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Bioventus (NASDAQ:BVS) stock moved upwards by 28.87% to $5.16. The market value of their outstanding shares is at $329.0 million. The company's, Q1 earnings came out today. Design Therapeutics (NASDAQ:DSGN) stock rose 28.49% to $4.69. The market value of their outstanding shares is at $264.9 million. Acutus Medical (NASDAQ:AFIB) stock moved upwards by 24.11% to $0.13. The company's market cap stands at $3.9 million. Oragenics (AMEX:OGEN) shares moved upwards by 22.78% to $1.33. The market valu
Piper Sandler analyst Yasmeen Rahimi upgrades Design Therapeutics (NASDAQ:DSGN) from Neutral to Overweight and raises the price target from $6 to $12.
The Dow Jones index closed lower by over 150 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform. FTC Solar The Trade: FTC Solar, Inc. (NASDAQ:FTCI) Director Ahmad R Chatila acquired a total of 92,600 shares an average price of $0.55. To acquire these shares, it cost around $50,930. What’s Happening: On March 13, FTC Solar posted upbeat quarte
RBC Capital analyst Leonid Timashev reiterates Design Therapeutics (NASDAQ:DSGN) with a Sector Perform and maintains $4 price target.
Wedbush analyst Laura Chico reiterates Design Therapeutics (NASDAQ:DSGN) with a Neutral and maintains $5 price target.
New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Programs to Clinical Proof-o
Design Therapeutics (NASDAQ:DSGN) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.31) by 32.26 percent. This is a 32.26 percent increase over losses of $(0.31) per share from the same period last year.
Companies Reporting Before The Bell • Tencent Music Enter Gr (NYSE:TME) is projected to report quarterly earnings at $0.14 per share on revenue of $931.97 million. • HUYA (NYSE:HUYA) is likely to report quarterly loss at $0.12 per share on revenue of $210.04 million. • Caleres (NYSE:CAL) is expected to report quarterly earnings at $0.85 per share on revenue of $694.33 million. • XPeng (NYSE:XPEV) is likely to report quarterly loss at $0.46 per share on revenue of $1.86 billion. • Core & Main (NYSE:CNM) is likely to report quarterly earnings at $0.35 per share on revenue of $1.43 billion. • Citi Trends (NASDAQ:CTRN) is likely to report quarterly earnings at $0.79 per share on revenue of